Clinical Trial Update: A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS [Phase 3]

View source ↗

Summary

Phase 3 trial assessing long-term safety of arbaclofen extended-release tablets for spasticity due to multiple sclerosis; study completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Spasticity

Drugs mentioned

• Arbaclofen Extended-Release Tablets (arbaclofen)

Snippet

Sponsor: RVL Pharmaceuticals, Inc. | Conditions: Multiple Sclerosis, Spasticity, Muscle | Phase 3 | Status: COMPLETED | Results posted: 2022-07-15